Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.34 |
| ▸ | CCR5 | P51681 | 4/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.33 |
| ▸ | IGF1R | P08069 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.33 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | SLC5A1 | P13866 | 4/20 | 0.31 |
| ▸ | SLC5A2 | P31639 | 4/20 | 0.31 |
| ▸ | PTPRC | P08575 | 1/20 | 0.31 |
| ▸ | PTPRG | P23470 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL499730 | 0.86 | CYP11B1 (0.38) | HTR2ASLC6A4KCNH2IGF1RALOX15 | |
| SCHEMBL500031 | 0.83 | SLC6A4 (0.37) | HTR2ASLC6A4KCNH2CCR5SLC6A2 | |
| SCHEMBL500175 | 0.82 | CA2 (0.38) | HTR2ASLC6A4KCNH2SLC5A1SLC5A2 | |
| SCHEMBL12782162 | 0.81 | CCR5 (0.47) | HTR2ASLC6A4KCNH2CCR5 | |
| SCHEMBL29198766 | 0.81 | HTR2A (0.37) | HTR2ASLC6A4KCNH2CCR5TAAR1 | |
| SCHEMBL499758 | 0.79 | HTR2A (0.32) | HTR2ASLC6A4KCNH2CCR5SLC5A1 | |
| SCHEMBL1457579 | 0.78 | APP (0.40) | HTR2ASLC6A4KCNH2CCR5SLC6A2 | |
| SCHEMBL17842 | 0.78 | MEN1 (0.46) | HTR2ASLC6A4KCNH2CCR5ALOX15 | |
| SCHEMBL499287 | 0.78 | SLC5A2 (0.38) | HTR2ASLC6A4KCNH2CCR5SLC6A2 | |
| SCHEMBL37715 | 0.78 | SLC5A2 (0.47) | HTR2ASLC6A4KCNH2CCR5SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3318562-A2 | BENZYLBENZENE DERIVATIVES AND METHODS OF USE | Theracos Sub, LLC (US) | 2018-05-09 | — | — | EP | disclosed |
| EP-3318562-A2 | BENZYLBENZENE DERIVATIVES AND METHODS OF USE | Theracos Sub, LLC (US) | 2018-05-09 | — | — | EP | disclosed |
| US-8802637-B2 | Benzylbenzene derivatives and methods of use | THERACOS, INC. (US) | 2014-08-12 | — | — | US | disclosed |
| US-8802637-B2 | Benzylbenzene derivatives and methods of use | THERACOS, INC. (US) | 2014-08-12 | — | — | US | disclosed |
| US-8802637-B2 | Benzylbenzene derivatives and methods of use | THERACOS, INC. (US) | 2014-08-12 | — | — | US | disclosed |
| US-20140031300-A1 | BENZYLBENZENE DERIVATIVES AND METHODS OF USE | THERACOS, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-20140031300-A1 | BENZYLBENZENE DERIVATIVES AND METHODS OF USE | THERACOS, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-20140031300-A1 | BENZYLBENZENE DERIVATIVES AND METHODS OF USE | THERACOS, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-8575321-B2 | Benzylbenzene derivatives and methods of use | THERACOS, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-8575321-B2 | Benzylbenzene derivatives and methods of use | THERACOS, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-7838499-B2 | Benzylbenzene derivatives and methods of use | THERACOS, INC. (US) | 2010-11-23 | — | — | US | disclosed |
| US-7838499-B2 | Benzylbenzene derivatives and methods of use | THERACOS, INC. (US) | 2010-11-23 | — | — | US | disclosed |
| US-7838499-B2 | Benzylbenzene derivatives and methods of use | THERACOS, INC. (US) | 2010-11-23 | — | — | US | disclosed |
| CN-101790311-A | Benzylbenzene derivatives and using method | THERACOS INC | 2010-07-28 | — | — | CN | disclosed |
| EP-2187742-A1 | BENZYLBENZENE DERIVATIVES AND METHODS OF USE | Theracos, Inc. (US) | 2010-05-26 | — | — | EP | disclosed |
| US-20090118201-A1 | BENZYLBENZENE DERIVATIVES AND METHODS OF USE | THERACOSBIO, LLC | 2009-05-07 | — | — | US | disclosed |
| US-20090118201-A1 | BENZYLBENZENE DERIVATIVES AND METHODS OF USE | THERACOSBIO, LLC | 2009-05-07 | — | — | US | disclosed |
| US-20090118201-A1 | BENZYLBENZENE DERIVATIVES AND METHODS OF USE | THERACOSBIO, LLC | 2009-05-07 | — | — | US | disclosed |
| WO-2009026537-A1 | BENZYLBENZENE DERIVATIVES AND METHODS OF USE | THERACOS, INC. (US) | 2009-02-26 | — | — | WO | disclosed |
| WO-2009026537-A1 | BENZYLBENZENE DERIVATIVES AND METHODS OF USE | THERACOS, INC. (US) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118201-A1 | BENZYLBENZENE DERIVATIVES AND METHODS OF USE | SLC5A2, SLC5A1, SLC2A4 | HTR2A 1353/4885SLC6A4 35/4885KCNH2 705/4885 |
| US-20140031300-A1 | BENZYLBENZENE DERIVATIVES AND METHODS OF USE | SLC5A2, SLC5A1, SLC2A4 | HTR2A 1353/4885SLC6A4 35/4885KCNH2 705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.